RxDoctor Payments Data

Shawn Miller, MD

Internal Medicine · Bonita Springs, FLNPI 1124106745

Payments from drug & device makers

$2,504in general payments, 2019–2025

Across 66 payments — averaging $37.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$507
  • Amgen$350
  • Abbott$293
  • Amarin Pharma, Inc.$288
  • Pfizer$175
  • GSK$159
  • plus $732 from 14 others

What the payments were for

  • Food & beverage$2,504100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,504 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$519,893
Medicare patients
697
Services billed
18,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$81,306
OzempicSemaglutide47$60,497
JardianceEmpagliflozin34$57,945
MounjaroTirzepatide48$53,562
XareltoRivaroxaban30$46,275
RybelsusSemaglutide18$46,234
ProliaDenosumab18$32,080
JanuviaSitagliptin Phosphate20$30,377
VascepaIcosapent Ethyl20$19,300
MyrbetriqMirabegron13$11,071
Rosuvastatin Calcium661$8,206
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$7,110
SynthroidLevothyroxine Sodium112$6,436
Praluent PenAlirocumab11$5,607
Amlodipine Besylate712$5,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$507$106,73265 claims
PfizerEliquis$175$81,30660 claims
Boehringer IngelheimJardiance$21$57,94534 claims
Lilly USA, LLCMounjaro$131$53,56248 claims
Johnson & JohnsonXarelto$19$46,27530 claims
AmgenProlia$350$32,08018 claims
MerckJanuvia$19$30,37720 claims
GSKAnoro Ellipta$159$7,11012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bonita Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →